MAPT and Alzheimer disease: Abnormal tau phosphorylation correlates with alterations in Bmal1 protein levels (Niu et al., 2021), while in patients with AD, methylation of Bmal1, indicating Bmal1 activity reduction, was correlated with tau pathology assessed by CERAD score, night wake, and alterations in cognitive function of some dimensions (Hulme et al., 2020).